Objective: To establish the gene copy number status of receptor tyrosine kinase (RTK) and downstream signaling (DSS) genes genes in primary gastric cancer (primGC) and matched lymph node metastases (LNmet). Background: Evidence suggests that coamplification between RTKs and DSSs and conversion between primGC and LNmet are associated with resistance to targeted therapy. Methods: DNA from 237 Japanese primGC and 103 matched LNmet was analyzed using a newly developed multiplex ligation-dependent probe amplification (MLPA) probemix to investigate RTK (EGFR, HER2, FGFR2, and MET) and DSS (PIK3CA, KRAS, MYC, and CCNE1) gene copy number status. Results were compared between primGC and LNmet and related to clinicopathological data including survival. Results: A total of 150 (63%) primGC had either RTK or DSS amplification. DSS coamplification was more frequent than RTK coamplification in primGC and LNmets. Moreover, 70 (30%) GC showed a disconcordant RTK and/or DSS gene copy number status between primGC and LNmet, most common was negative conversion for DSS genes (n¼40 GC). The presence of RTK amplification in primGC was related to poorer survival in univariate analysis (P¼0.04). Conclusions: This is the first and most comprehensive study in gastric cancer investigating the concordance between gene copy number status of targetable RTKs and downstream signaling oncogenes in primGC and LNmets. Future studies need to establish whether the relative high frequency of RTK and DSS coamplification and/or the relative high rate of negative conversion in LNmet can potentially explain recent failures of RTK targeted therapy in gastric cancer patients.
D
espite a decline in incidence over the past decade, gastric cancer (GC) remains a major cause of global cancer mortality. 1 GC is particularly common in Asian countries 2 with the highest incidences reported in South Korea and Japan. 3 Amplification of receptor tyrosine kinases (RTKs) such as EGFR, HER2, FGFR2, and MET has been associated with GC pathogenesis and tumor progression. [4] [5] [6] [7] Recent studies including our own seem to indicate that RTK gene amplification in primary GC (primGC) occurs in a mutually exclusive manner suggesting that targeting an individual RTK may be an effective treatment. [8] [9] [10] The ToGA trial demonstrated benefit from HER2 targeted treatment using trastuzumab in patients with HER2 positive metastatic GC. 11, 12 However, all other currently available HER2, EGFR or MET targeted drugs (lapatinib, T-DM1, cetuximab, panitumumab, rilotumumab, and onartuzumab) have been less successful in GC patients raising the question about potential mechanisms of resistance against RTK targeted therapy. 13, 14 Based on recent studies in colorectal cancer, 15, 16 breast cancer [17] [18] [19] and non-small cell lung cancer cell lines, 20, 21 one suggested potential resistance mechanism could be co-existing amplifications of genes located downstream of RTK such as KRAS, PIK3CA, CCNE1 and MYC (collectively called downstream signaling (DSS) genes from hereon). [15] [16] [17] [18] [19] [20] 22 In GC cell lines, coamplification of MET and KRAS was related to resistance to MET inhibitors and MET amplification to resistance to the HER2 and EGFR targeted drug lapatinib. 23 Furthermore, coamplification of EGFR and HER2 has been associated with HER2 targeted therapy resistance in GC. 24 A second potential resistance mechanism could be related to genetic heterogeneity resulting in a discordant gene copy number From the status between primary cancer and metastatic site 25 as reported recently in cancers of breast, 26 colorectal, 27 renal, 28 larynx/pharynx, 29 and liver. 30 In GC, up to 10% discordance of HER2 gene copy number status between primGC and matched lymph node metastasis has been reported 31, 32 and was related to poorer prognosis. 33 However, the concordance of the gene copy number status between primGC and matched lymph node metastasis (LNmet) has not been investigated for other RTKs or DSSs and there are no studies evaluating the presence of RTK and DSS gene coamplifications in this context.
We hypothesised that (i) coamplification of RTK (HER2, EGFR, MET, and FGFR2) and DSS (PIK3CA, KRAS, CCNE1, and MYC) is a common phenomenon in primGC, (ii) patients with coamplification of RTK and DSS in the primGC have the poorest overall survival, and (iii) the RTK and DSS gene copy number status will only be discordant between primGC and their matched LNmet in a minority of patients.
The aim of this study was to develop a new multiplex ligationdependent probe amplification (MLPA) probemix for the simultaneous assessment of RTKs (EGFR, FGFR2, MET, and HER2) and DSSs (KRAS, PIK3CA, CCNE1, and MYC) gene copy number status using DNA extracted from formalin fixed paraffin embedded tissue of primGC and matched LNmet and to establish the relationship between RTKs and DSSs gene copy number status with clinicopathological data and patient survival.
MATERIAL AND METHODS

Patients
After quality control, results were available from 237 patients with TNM 7th edition 34 stage II/III/IV gastric cancer who underwent potentially curative surgery at the Kanagawa Cancer Center Hospital (KCCH, Yokohama, Japan) between 2001 and 2010. A total of 101 (43%) patients were treated by surgery alone and 136 patients by surgery and adjuvant cytotoxic chemotherapy. None of the patients included in this study received targeted therapy. Demographical and clinicopathological data including depth of invasion (pT category), lymph node status (pN category), and distant metastasis (pM category), histological subtype according to Lauren classification 35 and tumor location according to the Japanese classification 36 were retrieved from local hospital records. Patient follow-up data and other parameters were obtained from histopathology reports and hospital records. Median follow-up time from surgery was 3.5 years, ranging from 0.3 to 9.5 years. This study was approved by the Local Research Ethics Committee. DNA from 13 GC cell lines (CLS145, HS746T, KATOIII,  MKN1, MKN7, NCI-N87, NUGC4, SNU16, YCC1, YCC11, YCC3,  YCC7 , and YCC9) with previously described gene copy number status 9 was extracted using the Qiagen genomic DNA extraction kit (Qiagen, Hilden, Germany) according to the instructions of the manufacturer and used to assess the sensitivity and specificity of the newly developed Multiplex Ligation Probe Amplification (MLPA) probemix.
Gastric Cancer Cell Lines
DNA was extracted from eight EDTA blood samples from healthy human donors using the Qiagen DNAeasy Blood and Tissue kit (Qiagen) according to the instructions of the manufacturer and used as reference sample for the GC cell lines in the MLPA probemix.
DNA Extraction from Gastric Cancer Tissue Samples
All hematoxylin/eosin stained slides from all 241 formalin fixed paraffin embedded (FFPE) gastrectomy specimens were reviewed. From all patients, a block from the primary tumor with the highest number of tumor cells per area was selected. From 128 patients with regional lymph node metastases, a block from the lymph node metastasis with the highest number of tumor cells per area was selected. DNA extraction was performed as described previously. 37 DNA concentration was measured by ND-100 Spectrophotometer (Labtech International via Ozyme SAS, St Quentin en Yveline, France) and adjusted to a final concentration of 100ng/mL. DNA from 12 normal FFPE tonsils was extracted using the same method, pooled and used as reference sample in the MLPA probemix.
MLPA Experiment
The MLPA protocol by Schouten et al 38 was slightly modified by increasing the number of PCR cycles from 33 to 35. MLPA probemix and reagents (Salsa MLPA reagent kit, Salsa PCR reagents, Salsa polymerase, Ligase-65) were developed and supplied by MRCHolland B.V., Amsterdam, The Netherlands. Each experimental run included DNA from GC cell lines, GC tissue [primary GC (primGC) and/or lymph node metastasis (LNmet)], reference sample (blood or tonsils), and negative controls (no DNA).
The first 90 cases were run in duplicates to assess reproducibility of results between runs. In 7 out of 720 (1%) of duplicates, there was a different result which would lead to a different gene copy number status class. Considering this high degree of reproducibility, it was felt that running samples in duplicates for the entire cohort was unnecessary.
The MLPA reaction product was sequenced on an ABI 3130 XL Sequencer (ABI Biosystems, CA). The output files from the sequencer (FSA files) were imported into Coffalyser.Net software version 130202.2357 39 for analysis. Samples with a Coffalyser analysis score (CAS) of less than 50% were considered to be of poor quality and excluded from further analyses. Failed experiments were repeated at least twice before a case was finally excluded from the analyses. Four primGC and fifteen LNmet had to be excluded after Coffalyser quality control analysis (Fig. 1) .
Reference samples (DNA from blood or tonsils as appropriate) with a CAS of 100% were used to determine the normal range of values for the peak height recognition. Based on the results from our normal reference samples and in accordance with previously published studies, 40, 41 we set the thresholds as follows: a gene copy number ratio of less than 0.80 was categorised as 'loss,' between 0.80 to 1.30 as 'normal,' between 1.31 to 2.00 as 'low level amplification,' between 2.01 to 5.00 as 'high level amplification,' and above 5.00 as 'very high level amplification.'
MLPA Assay
For further details on the MLPA probemix development, data analysis, use of competitor mixes for very highly amplified genes and studies to validate the assay, see supplementary document Table S1 , S2 and Figure S1 , http://links.lww.com/SLA/B123.
Statistical Analyses
Statistical analyses were performed using PASW Statistics 21 (IBM Corporation, NY) analyzing the gene copy number status of receptor tyrosine kinases (RTKs) EGFR, FGFR2, MET, and HER2 and downstream signaling pathway genes (DSSs) KRAS, PIK3CA, CCNE1, and MYC. All analyses described below were performed separately for primGC and LNmet. PrimGC or LNmet with low, high and very high level amplification (see MLPA experiment description above) were grouped together as 'amplification' and compared with samples with deletion or normal gene copy number status.
Coamplification was defined as 2 or more genes having a gene copy number ratio >1. 30 . The x
2 test was used to analyze the relationship between gene copy number statuses of different genes. The relationship between gene copy number status and clinicopathological variables in the primGC and gene copy number status in the LNmet was analyzed using the KruskalWallis test.
For survival analyses, primGC or LNmet with a gene copy number ratio of all RTK genes 1.30 were classified as 'no RTK amplification', with a gene copy number ratio of a single RTK gene >1.30 were classified as 'RTK amplification' and those with a gene copy number ratio of more than one RTK gene >1.30 were classified as 'RTK coamplification'. The same classification was used for DSS gene copy number status. GC with no DSS amplification and no RTK amplification were compared with GC with no DSS amplification and RTK amplification, DSS amplification and no RTK amplification, and with DSS amplification and RTK amplification.
In cases with amplifications, the status of the amplified gene(s) was compared between primGC and LNmet to identify so called 'conversion': (i) negative conversion was defined as gene amplification (copy number >1.30) detectable in the primGC that was not detectable in the matched LNmet; (ii) positive conversion was defined as gene amplification detectable in the LNmet which was not detectable in the matched primGC; and (iii) no conversion was defined as gene amplification detectable in both, primGC and LNmet. Univariate survival analyses were performed using the Kaplan Meier method and log rank test. Multivariate analyses were performed using Cox regression proportional hazard model including TNM stage and variable of interest in the model. P < 0.05 were considered significant.
RESULTS
MLPA Analysis of Gene Copy Number Status in Primary Gastric Cancer (PrimGC)
Results from 237 primGC were available for final analyses (Fig. 1) . The median (range) age of the study cohort was 65 years (35-85 years), for details on patients' characteristics see Table 1 .
In primGC, the most frequently amplified gene was PIK3CA (n ¼ 60, 25%) followed by
, and MET (n ¼ 11, 4%). For details on the frequency of normal gene copy number and losses see supplementary document Table S3 , http://links.lww.com/SLA/B123.
MLPA Analysis of Gene Copy Number Status in Lymph Node Metastasis (LNmet)
Results from 103 LNmet were available for final analyses (Fig. 1) . In LNmet, the most frequently amplified gene was MYC (n ¼ 27, 26%) followed by PIK3CA (n ¼ 18, 18%), KRAS (n ¼ 12, 11%), CCNE1 (n ¼ 9, 9%), HER2 (n ¼ 7, 7%), FGFR2 (n ¼ 7, 7%), EGFR (n ¼ 5, 5%), and MET (n ¼ 2, 2%). For details on the frequency of normal gene copy number and losses see supplementary document Table S3 , http://links.lww.com/SLA/B123.
RTK and DSS Gene Co-Amplification in Primary Gastric Cancer
There were 86 of the 237 (36%) primGC with neither DSS nor RTK amplification, 74 (31%) primGC with DSS amplification without RTK coamplification, 25 (11%) primGC with RTK coamplification without DSS coamplification and 52 (22%) primGC had coamplification of RTK and at least one DSS (Table S4 , http:// links.lww.com/SLA/B123).
Coamplification of DSS genes was present in 48 (20%) primGC and was more common than RTK coamplifications (n ¼ 21, 9%). High level coamplification (gene copy number > 2.00) of RTK was not detected and was rare for DSS (n ¼ 4, 2%). For details about the frequency of coamplification of individual genes see Venn diagram supplementary document Figure S2 , http://links.lww.com/ SLA/B123.
RTK and DSS Gene Coamplification in Lymph Node Metastasis
There were 45 of the 103 (44%) LNmet with neither DSS nor RTK amplification, 39 (37%) LNmet with DSS amplification without RTK coamplification, 9 (9%) LNmet with RTK amplification without DSS coamplification, and 10 (10%) LNmet had coamplification of RTK and at least one DSS (Table S4 , http://links.lww.com/ SLA/B123). Coamplification of DSS genes was present in 14 (14%) LNmet and was more common than RTK coamplifications (n ¼ 2, 2%). High level coamplification (gene copy number > 2.00) of RTK occurred in 1 LNmet (1%) and of DSS in 2 LNmet (2%).
Comparison of Gene Copy Number Status Between Primary Gastric Cancer and Matched Lymph Node Metastasis
Seventy (68%) of the 103 patients with results from primGC and matched LNmet showed conversion. When comparing gene copy number status of individual genes between primGC and matched LNmet, there was a significant difference for KRAS (P < 0.001), MYC (P < 0.001), CCNE (P < 0.001), HER2 (P ¼ 0.005), and FGFR2 (P < 0.001), whereas PIK3CA, EGFR, and MET gene copy number status was similar (all P > 0.05).
Considering all RTK and DSS genes together, 15 patients (21%) had positive (primGC not amplified, LNmet amplified) and negative conversions (primGC amplified, LNmet not amplified), 38 patients (54%) had negative conversions only, and 17 patients (24%) had positive conversions only.
Considering RTK genes only, a total of 33 patients (32%) had a conversion: 2 patients (6%) had positive and negative conversions, 25 patients (76%) had negative conversions only, and 6 patients (18%) had positive conversions only.
Considering DSS genes only, a total of 56 (54%) patients had a conversion: 10 patients (19%) had positive and negative conversions, 30 patients (54%) had negative conversions only, and 16 patients (29%) had positive conversions only.
Frequencies of conversion per individual gene are shown in Patients with RTK amplification in the primGC had a significantly worse survival than patients without RTK amplification (P ¼ 0.040, Fig. 2A ). However, multivariate analyses including primGC RTK gene copy number status (RTK amplification vs no RTK amplification) and TNM stage in the model showed that primGC RTK copy number status was not an independent prognostic marker (hazard ratio, HR: 1.457 95% confidence interval, CI: 0.995-2.135, P ¼ 0.053).
There was no significant survival difference for GC patients with or without DSS amplification in the primGC (P ¼ 0.153, Fig. 2B ).
There was no significant survival difference when patients were stratified by presence or absence of DSS and RTK coamplifications in the primGC (P ¼ 0.150, Fig. 2C ).
There was no significant survival difference for patients with or without RTK amplification, with or without DSS amplifications or with or without DSS and RTK coamplifications in the LNmet (all P > 0.05, Fig. 3 ).
There was no significant survival difference between GC patients with or without RTK and/or DSS conversion. There was also no survival difference when patients were stratified by the type of conversion (P 0.296, Fig. 4 ).
DISCUSSION
Recent studies including our own 9 suggest that approximately one third of gastric adenocarcinomas have mutually exclusive amplification of targetable receptor tyrosine kinases (EGFR, HER2, FGFR2, and MET). 9, 10 Preclinical and clinical studies suggest that (i) coamplification of receptor tyrosine kinase genes (RTK) and downstream signaling (DSS) genes could potentially alter targeted therapy efficacy 22, 23 and that (ii) gene copy number status discordance between primary tumor and metastases may influence response to RTK targeted treatment. [31] [32] [33] Currently, very little is known about the frequency of RTK and DSS coamplification and concordance of gene copy number status between primary gastric cancer (primGC) and matched lymph node metastasis (LNmet).
As part of this study, we designed a new multiplex ligation probe-dependent amplification (MLPA) probemix to allow simultaneous assessment of the gene copy number status of multiple RTKs and DSSs genes in DNA extracted from formalin fixed paraffin embedded gastric cancer specimens in a single experiment. 42, 43 Our validation studies demonstrated a high level of reproducibility, specificity and sensitivity and a low 19/369 (5%) technical dropout rate suggesting that the newly developed MLPA assay could be a clinically useful routine screening method to assess RTK and DSS gene copy number status.
Our study confirmed previous reports 9, 10 that approximately 30% GC have at least 1 RTK amplified and that the presence of RTK amplification in the primary tumor is associated with poorer survival (Fig. 2A) .
The coamplification frequency of HER2 and EGFR, HER2, and MET, and of FGFR2 and MET in the current study is similar to that reported previously. 9, [44] [45] [46] Furthermore, our study confirmed that high level RTK coamplifications are mutually exclusive events as reported previously. 9, 10 In addition, we found that low level RTK coamplifications can occur, which may explain some of the inconsistencies reported in the literature 9, [44] [45] [46] where the definition of what constitutes an amplification varies, see supplementary document Table S6 , http://links.lww.com/SLA/B123. The current study supports the previously reported finding that amplification of EGFR, HER2, MYC, and CCNE1 is more frequent in intestinal type GC. 47, 48 This is the first study to demonstrate that RTK and DSS coamplification is a common event in primary GC. Importantly, this is the first study to identify a substantial subgroup of GC patients (36%) with neither RTK nor DSS amplification suggesting that there is a subgroup of GC patients where the ERK/MAPK pathway may not be the main oncogenic driver. This finding is of potential clinical relevance as patients without RTK amplification in their primary GC had better overall survival and thus might require a different therapy approach.
Finally, this is the most comprehensive study in GC investigating the concordance between the gene copy number statuses of targetable receptor tyrosine kinases and downstream signaling oncogenes in primary tumor and matched lymph node metastasis demonstrating that the gene copy number status of the majority of investigated genes differs in up to 68% GC between the primGC and the LNmet. However the conversion of RTK or DSS genes does not appear to influence survival (Fig. 4) . (30) 12 (29) 59 (30) 6 (25) 65 (31) 4 (37) 67 ( 3 (12) 40 (19) 7 (17) 36 (18) 3 (13) 40 (19) 2 (18) 41 (18) pT3 1 (4) 30 (14) 5 (12) 26 (13) 5 (21) 26 (12) 1 (9) 30 (13) pT4a 21 (84) 136 (64) 29 (70) 128 (6) 16 (66) 141 (66) (25) 9 (21) 49 (25) 5 (21) 53 (25) 1 (9) 57 (25) pN2 6 (24) 57 (27) 10 (24) 53 (27) 8 (33) 55 (26) 6 (55) 57 (25) pN3a 7 (28) 54 (25) 11 (26) 50 (26) 3 (12) 58 (27) 1 (9) 60 (27) pN3b 2 (4) 16 (7) 4 (10) 14 (7) 4 (17) 14 (7) 2 (18) 16 (7 (5) 1 (2) 10 (5) 1 (4) 10 (5) 3 (27) (5) 1 (2) 10 (5) 1 (4) 10 (5) 3 (27) (20) 8 (17) 35 (18) 9 (20) 34 (18) 8 (21) 35 (18) pT3 14 (23) 17 (10) 9 (19) 22 (12) 6 (14) 25 (13) 11 (28) 20 (10) (25) 15 (32) 43 (23) 11 (25) 47 (24) 15 (38) 43 (22) pN2 18 (30) 45 (25) 12 (26) 51 (27) 11 (25) 52 (27) 10 (26) 53 (27) pN3a 18 (30) 43 (24) 10 (21) 51 (27) 12 (27) 49 (25) 8 (21) 53 (27) pN3b 4 (6) 14 (9) 3 (6) 15 (7) 3 (7) 15 (8) A, Kaplan-Meier survival analysis showed no difference in overall survival when patients were stratified by RTK gene copy number status of the lymph node metastasis. B, Kaplan-Meier survival analysis showed no difference in overall survival when patients were stratified by DSS copy number status of the lymph node metastasis. C, Kaplan-Meier survival analysis showed no difference in overall survival when patients were stratified by combining the RTK and DSS gene copy number status of the primary tumor. Key:
The HER2 gene copy number status concordance between primGC and LNmet is lower in the current study than reported in a recent meta-analysis. 49 Nevertheless, the meta-analysis also showed a higher negative than positive conversion rate as demonstrated in the current study. These different results could be related to differences in case mix, number of investigated cases per study, patient ethnicity or to the use of different experimental platforms to assess HER2 gene copy number status. Although there is good evidence supporting similar specificity and sensitivity of the MLPA assay compared with the FISH method, 40, 50 the MLPA assay is unable to distinguish between polysomy and amplification that could explain our relatively higher frequencies in comparison to the current literature.
The results from selected RTK and DSS gene copy number analyses in our study support the current model hypothesis that metastatic tumor cells in the lymph node may constitute a cell population with a different genetic makeup compared to the matched primary tumor. The clinically undetected 'loss' of an amplification of a RTK gene in a metastatic site that was present in the primary tumor may potentially render the targeted drug inefficient. This issue could potentially be addressed by investigating the gene copy number status in the primary tumor as well as in the metastatic site.
This study has some limitations. This is a retrospective study and thus we were unable to assess the clinical relevance of coamplifications of RTK and DSS with respect to resistance to RTK targeted therapy as patients in this study did not receive targeted therapy. Therefore, the predictive value of RTK/DSS coamplification and/or genetic conversion between primary cancer and metastasis in gastric cancer patients remains to be investigated.
Furthermore, this study focused on TNM stage II, III, and IV Japanese GC and further prospective studies need to demonstrate that the results from this study can be reproduced in GC from patients with other disease stages and/or ethnicities.
On the other hand, our study demonstrated that assessment of the gene copy number status of multiple selected genes is feasible with DNA from FFPE material (eg, routine histopathological material), in a timely fashion at relative low cost with high sensitivity, specificity, and excellent reproducibility using the new developed MLPA assay.
In conclusion, the emergence of targeted therapy acquired resistance mechanisms requires the development of clinically applicable and affordable methods screening for the drug targets and for genes related to the same pathway or other potential mechanisms that may impact drug effectiveness. This is the first study in gastric cancer demonstrating that coamplification of receptor tyrosine kinase (RTK) genes and downstream signaling (DSS) genes is more frequent than RTK amplification alone and that conversion of gene copy number status between primary GC and matched lymph node metastasis is more frequent than no conversion.
As patients in this study did not receive targeted therapy, we can currently only speculate that RTK and DSS coamplification in GC and discordance of gene copy number status between primary tumor and lymph node metastases in GC could potentially explain the recently seen failures of EGFR and MET targeted therapy in GC. Future studies are needed to investigate whether GC patients considered for RTK targeted therapy require gene copy number assessment of receptor tyrosine kinase genes and downstream signaling genes from primary tumor and lymph node metastasis to identify potential responders.
